Á lódáil...
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
BACKGROUND: PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Patients wi...
Na minha lista:
Foilsithe in: | Ann Oncol |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Oxford University Press
2017
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5452066/ https://ncbi.nlm.nih.gov/pubmed/28368437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx111 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|